Please use this identifier to cite or link to this item:

Full metadata record
DC FieldValueLanguage
dc.contributor.authorRodrigues, L. R.-
dc.contributor.authorRodrigues, Joana Lúcia Lima Correia-
dc.contributor.authorMachado, C. D.-
dc.contributor.authorKluskens, Leon-
dc.contributor.authorMota, M.-
dc.contributor.authorRocha, I.-
dc.contributor.authorFerreira, E. C.-
dc.description.abstractSYNBIOBACTHER – Engineering “therapeutic” bacteria Rodrigues LR, Rodrigues JL, Machado CD, Kluskens L, Mota M, Rocha I, Ferreira EC IBB-Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal Statistics show that over 1.3 million persons will be diagnosed with breast cancer worldwide this year, hence this is an enormously important health risk, and progress leading to enhanced survival is a global priority. Several strategies have been pursued over the years, whether searching new biomarkers, drugs or treatments. Ultrasound is often used to treat solid tumours. However, this technique is not always successful, as sometimes it just heats the tumour without destroying it. If it would be possible to link this treatment with the expression/release of a therapeutic agent, the joint effect could be more effective. Some efforts have been made in this direction, although to date the results have not been very encouraging; potential reasons include lack of precise control over administration of the drug. Therefore, the idea is to overcome this barrier through the use of synthetic and systems biology strategies to engineer a model bacterium to trigger release of a therapeutic agent concurrent with ultrasound treatment. The search for new cancer-fighting drugs has traditionally driven research efforts in this field. Curcumin, due to its attractive properties as a novel drug has recently attracted increased attention. Nevertheless, it is well known that it has a poor bioavailability. Cellular uptake is slow, and it is quickly metabolised once inside cells, requiring repetitive oral doses to achieve sufficient concentration inside the cells for therapeutic activity. Hence, the possibility of synthesizing curcumin in situ in a controlled way, as proposed in this project, provides a powerful alternative. References [1] Katsuyama Y, Matsuzawa M, Funa N, Horinouchi S, “Production of curcuminoids by Escherichia coli carrying an artificial biosynthesis pathway”, Microbiology (2008) 154:2620-2628. [2] Forbes NS, “Engineering the perfect (bacterial) cancer therapy”, Nat, Rev. Cancer (2010) 10:785-794.por
dc.publisherUniversidade do Minho. Centro de Engenharia Biológica (CEB)por
dc.subjectSynthetic biologyepor
dc.subjectColitherapeuticsbreast cancerpor
dc.titleSynbiobacther: engineering “therapeutic” bacteriapor
oaire.citationTitle3rd Meeting of the Institute for Biotechnology and Bioengineeringpor
Appears in Collections:CEB - Resumos em Livros de Atas / Abstracts in Proceedings

Files in This Item:
File Description SizeFormat 
Pages from Book of Abstracts IBB 2012.pdf301,77 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID